These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 27548695)

  • 1. Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa.
    Rohr JK; Ive P; Horsburgh CR; Berhanu R; Shearer K; Maskew M; Long L; Sanne I; Bassett J; Ebrahim O; Fox MP
    PLoS One; 2016; 11(8):e0161469. PubMed ID: 27548695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda.
    Ssempijja V; Nakigozi G; Chang L; Gray R; Wawer M; Ndyanabo A; Kasule J; Serwadda D; Castelnuovo B; Hoog AV; Reynolds SJ
    BMC Infect Dis; 2017 Aug; 17(1):582. PubMed ID: 28830382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Mortality With Delayed and Missed Switch to Second-Line Antiretroviral Therapy in South Africa.
    Bell Gorrod H; Court R; Schomaker M; Maartens G; Murphy RA
    J Acquir Immune Defic Syndr; 2020 May; 84(1):107-113. PubMed ID: 32032304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa.
    Fox MP; Cutsem GV; Giddy J; Maskew M; Keiser O; Prozesky H; Wood R; Hernán MA; Sterne JA; Egger M; Boulle A;
    J Acquir Immune Defic Syndr; 2012 Aug; 60(4):428-37. PubMed ID: 22433846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed switch of antiretroviral therapy after virologic failure associated with elevated mortality among HIV-infected adults in Africa.
    Petersen ML; Tran L; Geng EH; Reynolds SJ; Kambugu A; Wood R; Bangsberg DR; Yiannoutsos CT; Deeks SG; Martin JN
    AIDS; 2014 Sep; 28(14):2097-107. PubMed ID: 24977440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
    Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
    Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.
    Chang LW; Harris J; Humphreys E
    Cochrane Database Syst Rev; 2010 Apr; (4):CD008494. PubMed ID: 20393969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa.
    Evans D; Hirasen K; Berhanu R; Malete G; Ive P; Spencer D; Badal-Faesen S; Sanne IM; Fox MP
    AIDS Res Ther; 2018 Apr; 15(1):10. PubMed ID: 29636106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment outcomes of over 1000 patients on second-line, protease inhibitor-based antiretroviral therapy from four public-sector HIV treatment facilities across Johannesburg, South Africa.
    Shearer K; Evans D; Moyo F; Rohr JK; Berhanu R; Van Den Berg L; Long L; Sanne I; Fox MP
    Trop Med Int Health; 2017 Feb; 22(2):221-231. PubMed ID: 27797443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superior virologic and treatment outcomes when viral load is measured at 3 months compared to 6 months on antiretroviral therapy.
    Kerschberger B; Boulle AM; Kranzer K; Hilderbrand K; Schomaker M; Coetzee D; Goemaere E; Van Cutsem G
    J Int AIDS Soc; 2015; 18(1):20092. PubMed ID: 26403636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study.
    Hermans LE; Moorhouse M; Carmona S; Grobbee DE; Hofstra LM; Richman DD; Tempelman HA; Venter WDF; Wensing AMJ
    Lancet Infect Dis; 2018 Feb; 18(2):188-197. PubMed ID: 29158101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virological suppression and clinical management in response to viremia in South African HIV treatment program: A multicenter cohort study.
    Hermans LE; Carmona S; Nijhuis M; Tempelman HA; Richman DD; Moorhouse M; Grobbee DE; Venter WDF; Wensing AMJ
    PLoS Med; 2020 Feb; 17(2):e1003037. PubMed ID: 32097428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria.
    Gilks CF; Walker AS; Munderi P; Kityo C; Reid A; Katabira E; Goodall RL; Grosskurth H; Mugyenyi P; Hakim J; Gibb DM;
    PLoS One; 2013; 8(2):e57580. PubMed ID: 23437399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration.
    Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration
    Lancet HIV; 2019 Feb; 6(2):e105-e115. PubMed ID: 30723008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simplifying switch to second-line antiretroviral therapy in sub Saharan Africa: predicted effect of using a single viral load to define efavirenz-based first-line failure.
    Shroufi A; Van Cutsem G; Cambiano V; Bansi-Matharu L; Duncan K; Murphy RA; Maman D; Phillips A
    AIDS; 2019 Aug; 33(10):1635-1644. PubMed ID: 31305331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa.
    Wandeler G; Gerber F; Rohr J; Chi BH; Orrell C; Chimbetete C; Prozesky H; Boulle A; Hoffmann CJ; Gsponer T; Fox MP; Zwahlen M; Egger M;
    Antivir Ther; 2014; 19(5):521-5. PubMed ID: 24296645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration.
    Davies MA; Moultrie H; Eley B; Rabie H; Van Cutsem G; Giddy J; Wood R; Technau K; Keiser O; Egger M; Boulle A;
    J Acquir Immune Defic Syndr; 2011 Mar; 56(3):270-8. PubMed ID: 21107266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.
    Boender TS; Hoenderboom BM; Sigaloff KC; Hamers RL; Wellington M; Shamu T; Siwale M; Labib Maksimos EE; Nankya I; Kityo CM; Adeyemo TA; Akanmu AS; Mandaliya K; Botes ME; Ondoa P; Rinke de Wit TF
    Clin Infect Dis; 2015 Dec; 61(11):1749-58. PubMed ID: 26240203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes after virologic failure of first-line ART in South Africa.
    Murphy RA; Sunpath H; Lu Z; Chelin N; Losina E; Gordon M; Ross D; Ewusi AD; Matthews LT; Kuritzkes DR; Marconi VC;
    AIDS; 2010 Apr; 24(7):1007-12. PubMed ID: 20397305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching to second-line ART in relation to mortality in a large Tanzanian HIV cohort.
    Hawkins C; Hertzmark E; Spiegelman D; Muya A; Ulenga N; Kim S; Khudyakov P; Christian B; Sando D; Aris E; Fawzi W
    J Antimicrob Chemother; 2017 Jul; 72(7):2060-2068. PubMed ID: 28387836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.